Earnings call transcript: Aquestive Therapeutics misses Q3 2026 estimates

Aquestive reported Q3 2026 adjusted loss of $0.18 per share versus the $0.12 consensus loss and revenue of $7.5 million versus $11.02 million expected; reported revenue fell 40.6% year over year to $7.6 million, mainly due to lower Suboxone orders. The company maintained 2026 guidance of $46–$50 million in revenue and a $30–$35 million adjusted EBITDA loss, and expects year-end cash above $70 million. The FDA accepted Anaphylm’s resubmission and set a March 16, 2027 PDUFA date; management is preparing a potential U.S. launch with about 75 sales representatives. Shares rose 2.71% to $3.985 in after-hours trading despite the earnings and revenue misses.

Analysis

The key asymmetry is that AQST’s equity is increasingly an approval-and-launch option, while its legacy supply business is too volatile to anchor near-term valuation. Management’s unchanged 2026 revenue range requires roughly $10–14 million in Q4 revenue based on nine-month results; failure to deliver would weaken the “order timing” explanation and raise questions about the base business. Verify Q4 orders and the guidance bridge rather than extrapolating from one quarter.

The March 2027 FDA decision is the dominant catalyst. Acceptance of a resubmission is procedural, not evidence of approval; management’s view that review is limited to CRL items and its commercial differentiation claims remain company assertions. If approved, the second-order risk is launch economics: payer access at a premium to generic injectors and adoption beyond a targeted prescriber set may take longer and cost more than a 75-rep plan implies. Conditional RTW/Oaktree financing mitigates launch funding risk only if approval and contractual conditions are met, so the stated cash balance should not be treated as equivalent to committed launch capital.

Contrarian read: the modest positive after-hours move may underweight the earnings-quality issue and payer execution, but a short ahead of a binary FDA event has poor asymmetry. ETON has Libervant commercial optionality and AQST remains its manufacturer, but milestones and royalties depend on approvals and sales; the transaction alone does not establish material near-term earnings contribution. Six-to-eighteen-month upside depends on approval, coverage quality, physician uptake and spend efficiency—not merely the regulatory date.

Key Decisions for Investors

• AQST: Do not chase the post-results move or initiate an outright short before the March 2027 decision. Reassess after the next filing/regulatory update and once option-implied volatility, liquidity and downside exposure are available; any pre-decision exposure should be strictly defined-risk and sized for a binary outcome.
• Set a near-term alert for Q4 revenue versus the approximately $10–14 million implied by unchanged full-year guidance. A miss, guidance cut, or further weakness in manufacturing/supply orders would falsify the benign order-timing thesis and support a more negative view of AQST’s non-launch business.
• Track payer coverage, price positioning versus generic auto-injectors and competing nasal epinephrine, and post-approval prescribing/launch spend. Weak coverage or uptake relative to sales-force expense would challenge the launch case even if FDA approval is secured.
• ETON: Treat Libervant as optionality, not a standalone long thesis yet. Verify approval timing, launch plans and evidence of demand before underwriting milestone or royalty value; AQST’s continued supply role links some upside to ETON’s execution.